Disease Landscape and Forecast Insights

The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with such agents, and thus branded…

The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…

The rising rates of antimicrobial resistance (AMR) have created an emergent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Since the emergence of the…

The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…

Rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have…

MARKET OUTLOOK The hospital-treated gram-negative infection (GNI) therapy market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug…

The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or bacterial species…

Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…

MARKET OUTLOOK Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents…

Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…

Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…